研究单位：[1]Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430000
研究目的：
A multicenter, open, single arm, phase II clinical trial was designed for myometrial invasive bladder cancer to evaluate the efficacy and safety of RC48-ADC combined with gemcitabine in preoperative neoadjuvant treatment of MIBC, and provide high-level clinical evidence for gemcitabine combined with ADC in the treatment of MIBC
